The risk score formula was associated with progression-free survival (PFS) in patients with NSCLC undergoing anti-PD-1/PD-L1 therapy in the GSE135222 cohort (HR = 4.26; 95% CI = 3.15–5.75; p = 0.04) (Figure 12A), and the AUC value for predicting the 12-month PFS was 0.702 (Figure 12B). Here, CD274 is linked to non-small cell lung carcinoma.